Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3050258 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: PlaceboDrug: LY3050258
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT01929707
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States
A Study of LY2409021 in Participants With Different Levels of Kidney Function
- Conditions
- Kidney Failure, ChronicRenal Insufficiency, Chronic
- Interventions
- Drug: LY2409021
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01929109
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, United Kingdom
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: Insulin GlargineBiological: LY2605541
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT01925989
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
A Study of Baricitinib and Omeprazole in Healthy Participants
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01925144
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: LY3090106 - SQBiological: Placebo - SQBiological: LY3090106 - IV
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 43
- Registration Number
- NCT01925157
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania
A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT01924299
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of LY2940680 in Japanese Participants With Advanced Cancers
- Conditions
- Neoplasm Metastasis
- Interventions
- Drug: LY2940680
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT01919398
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-858-255-5959 Mon - Fri from 9 AM to 5 PM Pacific Time (PST), or speak with your personal physician., Tokyo, Japan
An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 151
- Registration Number
- NCT01914666
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan
A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [^14C]-LY2835219
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01913314
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Baricitinib and Rifampicin in Healthy Participants
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01910311
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom